NDLI: Infliximab Extends the Duration until the First Surgery in Patients with Crohn's Disease

Content Provider	PubMed Central
Author	Aki, Sakatani Fujiya, Mikihiro Ito, Takahiro Inaba, Yuhei Ueno, Nobuhiro Kashima, Shin Tominaga, Motoya Moriichi, Kentaro Okamoto, Kotaro Tanabe, Hiroki Ikuta, Katsuya Ohtake, Takaaki Kono, Toru Furukawa, Hiroyuki Ashida, Toshifumi Yutaka, Kohgo
Copyright Year	2013
Abstract	Background/Aims. While biological drugs are useful for relieving the disease activity and preventing abdominal surgery in patients with Crohn's disease (CD), it is unclear whether the use of biological drugs in CD patients with no history of abdominal surgery is appropriate. We evaluated the effects of infliximab and other factors on extending the duration until the first surgery in CD patients on a long-term basis. Methods. The clinical records of 104 CD patients were retrospectively investigated. The cumulative nonoperation rate until the first surgery was examined with regard to demographic factors and treatments. Results. The 50% nonoperative interval in the 104 CD patients was 107 months. The results of a univariate analysis revealed that a female gender, the colitis type of CD, and the administration of corticosteroids, immunomodulators, or infliximab were factors estimated to improve the cumulative nonoperative rate. A multivariate analysis showed that the colitis type and administration of infliximab were independent factors associated with a prolonged interval until the first surgery in the CD patients with no history of abdominal surgery. Conclusions. This study suggests that infliximab treatment extends the duration until the first surgery in CD patients with no history of abdominal surgery. The early use of infliximab before a patient undergoes abdominal surgery is therefore appropriate.
Related Links	http://dx.doi.org/10.1155/2013/879491
Starting Page	879491
File Format	PDF
ISSN	23146133
e-ISSN	23146141
Journal	BioMed Research International
Volume Number	2013
Language	English
Publisher	Hindawi Publishing Corporation
Publisher Date	2013-01-01
Access Restriction	Open
Rights Holder	Hindawi Publishing Corporation
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Immunology and Microbiology Medicine Biochemistry, Genetics and Molecular Biology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences

Where Are All the Mycobacterium avium Subspecies paratuberculosis in Patients with Crohn's Disease?

Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis

Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

MRI for Crohn's Disease: Present and Future

Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment

Treatment of Crohn's disease with infliximab: first choice?

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects

Infliximab Extends the Duration until the First Surgery in Patients with Crohn's Disease

Similar Documents

Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences

Where Are All the Mycobacterium avium Subspecies paratuberculosis in Patients with Crohn's Disease?

Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis

Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

MRI for Crohn's Disease: Present and Future

Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment

Treatment of Crohn's disease with infliximab: first choice?

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects

Infliximab Extends the Duration until the First Surgery in Patients with Crohn's Disease